This is a single center, single arm, prospective, 12 week open label pilot trial of the
sodium-glucose cotransporter 2 inhibitor (SGLT2i), empagliflozin 10 mg oral daily, in
patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The target population for
enrollment will be subjects with ATTR-CM and either non-insulin dependent diabetes mellitus
or chronic kidney disease. The primary aim will be to assess the safety and tolerability of
empagliflozin 10 mg oral daily in subjects with heart failure secondary to ATTR, which remain
unexplored. The accrual target is 15 subjects. Consented subjects will be evaluated for
safety and tolerability of study drug, empagliflozin 10 mg oral daily, over a period of 12
weeks. Subjects will undergo a total of 6 study visits: 3 in-person and 3 telephone
follow-ups.